Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ciprofloxacin Garners No UK Concessions Despite Rises

Pricewatch UK – September 2020

Executive Summary

Despite the average trade price of ciprofloxacin shooting up in September, no UK price concessions were granted by the DHSC.

You may also be interested in...



Zonisamide Zooms Up In October

Zonisamide presentations saw average price increases of as much as five times in October, according to the latest UK figures from WaveData.

Moxonidine Rises Ramp Up In August

Moxonidine topped our table of Biggest Risers for the second month in a row, as UK prices that had doubled in July accelerated even more rapidly in August.

Moxonidine And Rasagiline See Triple-Digit Rises In July

Moxonidine led the price rises for established generics in the UK in July, with averages for the hypertension treatment more than doubling in some cases. However, among recently-launched products, rasagiline stood out with an average that was more than three times that of the previous month.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB150340

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel